Apollomics APLM
NASDAQ APLM
$23.86 -1.02 (-4.04%)
As of: Sep 10, 2026 · 11:04 AM EDT

Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025)

Apollomics' (APLM) quarterly Total Non-Current Liabilities came in at $3.6 million in Q4 2025, up 328.26% year-over-year from $835000.0 in Q4 2024, and down 29.12% quarter-over-quarter from $5.0 million in Q2 2025.

Analysis

Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends

Apollomics (APLM) has reported Total Non-Current Liabilities for 5 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 328.26% year-over-year to $3.6 million in Q4 2025; TTM through Dec 2025 was $3.6 million, a 328.26% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, up 328.26% from the prior year.
  • Total Non-Current Liabilities was $3.6 million for Q4 2025 at Apollomics, down from $5.0 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $512.2 million in Q4 2022 and troughed at -$212.9 million in Q4 2021.
  • A 5-year average of $39.0 million and a median of $1.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities plunged 99.88% in 2023 and surged 351.66% in 2025, its largest moves.
  • Over 5 years, Total Non-Current Liabilities stood at -$212.9 million in 2021, then soared by 340.64% to $512.2 million in 2022, then sank by 99.88% to $597000.0 in 2023, then jumped by 39.87% to $835000.0 in 2024, then surged by 328.26% to $3.6 million in 2025.
  • The last three Total Non-Current Liabilities figures came in at $3.6 million (Q4 2025), $5.0 million (Q2 2025), and $835000.0 (Q4 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 378.37 Mn
10 Apollomics 34.50 Mn 31.23 Mn - 3.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 3.58 Mn
Jun 30, 2025 5.05 Mn
Dec 31, 2024 835,000.00
Jun 30, 2024 1.12 Mn
Dec 31, 2023 597,000.00
Jun 30, 2023 1.55 Mn
Dec 31, 2022 512.24 Mn
Dec 31, 2021 -212.86 Mn